Remi Veillon

TL;DR: The frequency of genetic alterations, acceptable turnaround times in obtaining analysis results, and the clinical advantage provided by detection of a genetic alteration suggest that this nationwide molecular profiling of patients with advanced NSCLC provides a clinical benefit.

TL;DR: In certain subgroups, PFS was positively associated with PD-L1 expression (KRAS, EGFR) and with smoking status (BRAF, HER2) and the lack of response in the ALK group was notable.

TL;DR: It is suggested that HPD is more common with PD-1/PD-L1 inhibitors compared with chemotherapy in pretreated patients with NSCLC and is also associated with high metastatic burden and poor prognosis in patients treated with PD.

TL;DR: Among patients with advanced NSCLC with a confirmed MET exon 14 skipping mutation, the use of tepotinib was associated with a partial response in approximately half the patients, and adverse events led to permanent discontinuation of tEPotinib in 11% of the patients.

TL;DR: These results confirm the activity of targeted therapy in patients with BRAF-mutant lung adenocarcinoma and further trials are warranted to study combination therapies and drug resistance mechanisms.